Aaron M Udager1, Angelo M DeMarzo2, Yang Shi3,4, Jessica L Hicks2, Xuhong Cao4, Javed Siddiqui4, Hui Jiang3, Arul M Chinnaiyan1,4,5,6,7, Rohit Mehra1,4,6. 1. Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan. 2. Department of Pathology, The Sidney Kimmel Comprehensive Cancer Center and The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland. 3. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan. 4. Michigan Center for Translational Pathology, Ann Arbor, Michigan. 5. Department of Urology, University of Michigan Health System, Ann Arbor, Michigan. 6. Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, Michigan. 7. Howard Hughes Medical Institute, Ann Arbor, Michigan.
Abstract
BACKGROUND: Recurrent ERG gene fusions, the most common genetic alterations in prostate cancer, drive overexpression of the nuclear transcription factor ERG, and are early clonal events in prostate cancer progression. The nuclear transcription factor MYC is also frequently overexpressed in prostate cancer and may play a role in tumor initiation and/or progression. The relationship between nuclear ERG and MYC protein overexpression in prostate cancer, as well as the clinicopathologic characteristics and prognosis of ERG-positive/MYC high tumors, is not well understood. METHODS: Immunohistochemistry (IHC) for ERG and MYC was performed on formalin-fixed, paraffin-embedded tissue from prostate cancer tissue microarrays (TMAs), and nuclear staining was scored semi-quantitatively (IHC product score range = 0-300). Correlation between nuclear ERG and MYC protein expression and association with clinicopathologic parameters and biochemical recurrence after radical prostatectomy was assessed. RESULTS: 29.1% of all tumor nodules showed concurrent nuclear ERG and MYC protein overexpression (i.e., ERG-positive/MYC high), including 35.0% of secondary nodules. Overall, there was weak positive correlation between ERG and MYC expression across all tumor nodules (rpb = 0.149, P = 0.045), although this correlation was strongest in secondary nodules (rpb = 0.520, P = 0.019). In radical prostatectomy specimens, ERG-positive/MYC high tumors were positively associated with the presence of extraprostatic extension (EPE), relative to all other ERG/MYC expression subgroups, however, there was no significant association between concurrent nuclear ERG and MYC protein overexpression and time to biochemical recurrence. CONCLUSIONS: Concurrent nuclear ERG and MYC protein overexpression is common in prostate cancer and defines a subset of locally advanced tumors. Recent data indicates that BET bromodomain proteins regulate ERG gene fusion and MYC gene expression in prostate cancer, suggesting possible synergistic targeted therapeutics in ERG-positive/MYC high tumors. Prostate 76:845-853, 2016.
BACKGROUND: Recurrent ERG gene fusions, the most common genetic alterations in prostate cancer, drive overexpression of the nuclear transcription factor ERG, and are early clonal events in prostate cancer progression. The nuclear transcription factor MYC is also frequently overexpressed in prostate cancer and may play a role in tumor initiation and/or progression. The relationship between nuclear ERG and MYC protein overexpression in prostate cancer, as well as the clinicopathologic characteristics and prognosis of ERG-positive/MYC high tumors, is not well understood. METHODS: Immunohistochemistry (IHC) for ERG and MYC was performed on formalin-fixed, paraffin-embedded tissue from prostate cancer tissue microarrays (TMAs), and nuclear staining was scored semi-quantitatively (IHC product score range = 0-300). Correlation between nuclear ERG and MYC protein expression and association with clinicopathologic parameters and biochemical recurrence after radical prostatectomy was assessed. RESULTS: 29.1% of all tumor nodules showed concurrent nuclear ERG and MYC protein overexpression (i.e., ERG-positive/MYC high), including 35.0% of secondary nodules. Overall, there was weak positive correlation between ERG and MYC expression across all tumor nodules (rpb = 0.149, P = 0.045), although this correlation was strongest in secondary nodules (rpb = 0.520, P = 0.019). In radical prostatectomy specimens, ERG-positive/MYC high tumors were positively associated with the presence of extraprostatic extension (EPE), relative to all other ERG/MYC expression subgroups, however, there was no significant association between concurrent nuclear ERG and MYC protein overexpression and time to biochemical recurrence. CONCLUSIONS: Concurrent nuclear ERG and MYC protein overexpression is common in prostate cancer and defines a subset of locally advanced tumors. Recent data indicates that BET bromodomain proteins regulate ERG gene fusion and MYC gene expression in prostate cancer, suggesting possible synergistic targeted therapeutics in ERG-positive/MYC high tumors. Prostate 76:845-853, 2016.
Authors: Sarah Minner; Malaika Enodien; Hüseyin Sirma; Andreas M Luebke; Antje Krohn; Pascale S Mayer; Ronald Simon; Pierre Tennstedt; Julia Müller; Laura Scholz; Jan C Brase; Alvin Y Liu; Hartmut Schlüter; Klaus Pantel; Udo Schumacher; Carsten Bokemeyer; Thomas Steuber; Markus Graefen; Guido Sauter; Thorsten Schlomm Journal: Clin Cancer Res Date: 2011-07-26 Impact factor: 12.531
Authors: Emmanuel S Antonarakis; Daniel Keizman; Zhe Zhang; Bora Gurel; Tamara L Lotan; Jessica L Hicks; Helen L Fedor; Michael A Carducci; Angelo M De Marzo; Mario A Eisenberger Journal: Cancer Date: 2012-06-06 Impact factor: 6.860
Authors: Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan Journal: Nature Date: 2014-04-23 Impact factor: 49.962
Authors: C Sun; A Dobi; A Mohamed; H Li; R L Thangapazham; B Furusato; S Shaheduzzaman; S-H Tan; G Vaidyanathan; E Whitman; D J Hawksworth; Y Chen; M Nau; V Patel; M Vahey; J S Gutkind; T Sreenath; G Petrovics; I A Sesterhenn; D G McLeod; S Srivastava Journal: Oncogene Date: 2008-06-09 Impact factor: 9.867
Authors: Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides Journal: Nature Date: 2011-10-02 Impact factor: 49.962
Authors: Anastasia Wyce; Yan Degenhardt; Yuchen Bai; BaoChau Le; Susan Korenchuk; Ming-Chih Crouthame; Charles F McHugh; Robert Vessella; Caretha L Creasy; Peter J Tummino; Olena Barbash Journal: Oncotarget Date: 2013-12
Authors: Rohit Mehra; Yang Shi; Aaron M Udager; John R Prensner; Anirban Sahu; Matthew K Iyer; Javed Siddiqui; Xuhong Cao; John Wei; Hui Jiang; Felix Y Feng; Arul M Chinnaiyan Journal: Neoplasia Date: 2014-12 Impact factor: 5.715
Authors: Andreas Pettersson; Travis Gerke; Kathryn L Penney; Rosina T Lis; Edward C Stack; Nelma Pértega-Gomes; Giorgia Zadra; Svitlana Tyekucheva; Edward L Giovannucci; Lorelei A Mucci; Massimo Loda Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-15 Impact factor: 4.254
Authors: Vipulkumar Dadhania; Daniel Gonzalez; Mustafa Yousif; Jerome Cheng; Todd M Morgan; Daniel E Spratt; Zachery R Reichert; Rahul Mannan; Xiaoming Wang; Anya Chinnaiyan; Xuhong Cao; Saravana M Dhanasekaran; Arul M Chinnaiyan; Liron Pantanowitz; Rohit Mehra Journal: BMC Cancer Date: 2022-05-05 Impact factor: 4.638